© 2012 Therapharm a.s.
  About
  Products
  R&D
  Contacts
Products
Therapharm specializes in the production and R&D of

receptor agonists

,

receptor modulators

, compounds for receptor blocking and also receptor regulating and stimulating species. In the most of these cases peptide skeleton is used and up to 45 of the AAs and the pseudoAAs in the chain is presented, nevertheless the average

peptide

agonists are usually built from 25 to 35 AAs and pseudoAAs. The precision placing of pseudoAAs as e.g. D-AAs, 4-aminobenzoic acid, chemically modified AAs in the peptide chain makes it possible to obtain the agonist with unique binding parameters on the receptor along with low native toxicity, low xenobiotic activity, well controllable biodegradability. The Company is currently focused on three receptor active product areas:

cancer stem cell receptor agonists with enhanced and maximized binding affinity to specific cell line epitopes (commercially available CSC1000 and CSC2000 lines). The targeted cell lines are CD25, CD34, CD44 and CD133 possitive cancer stem cells. For quote requests, GMP availability please contact us.

stem cell receptor TGFBII agonists with possitive reversible (stimulating), negative reversible (suppressing) and negative irreversible (blocking) actioning (commercially available PLF line). The concept of the agonists is based on Azacycles' Receptor Shield technology. For quote requests, GMP availability please contact us.

stem cell receptor WNT agonists with possitive reversible (stimulating), negative reversible (suppressing) and negative irreversible (blocking) actioning. The concept of the agonists is based on Azacycles' Receptor Shield technology. The modipeptides of this group are in development. For general requests please contact us.

The Therapharm uses only solid phase chemical peptide synthesis, in case of longer chain peptides (> 15 AAs) usually the divergent strategy. It follows that high purity peptides are obtained, no endotoxines are present and the methodics is allways very well scalable. This is important if technology transfer to a third party is expected.